The transcription factors MyoD and Myf-5 control myoblast identity and differentiation. MyoD and Myf-5 manifest opposite cell cycle-specific expression patterns. Here, we provide evidence that MyoD plays a pivotal role at the G 2 /M transition by controlling the expression of p21 Waf1/Cip1 (p21), which is believed to regulate cyclin B-Cdc2 kinase activity in G 2 . In growing myoblasts, MyoD reaccumulates during G 2 concomitantly with p21 before entry into mitosis; MyoD is phosphorylated on Ser5 and Ser200 by cyclin B-Cdc2, resulting in a decrease of its stability and down-regulation of both MyoD and p21. Inducible expression of a nonphosphorylable MyoD A5/A200 enhances the MyoD interaction with the coactivator P/CAF, thereby stimulating the transcriptional activation of a luciferase reporter gene placed under the control of the p21 promoter. MyoD A5/A200 causes sustained p21 expression, which inhibits cyclin B-Cdc2 kinase activity in G 2 and delays M-phase entry. This G 2 arrest is not observed in p21
Myogenic differentiation is under the control of the MyoD family of b-HLH transcription factors (MRFs), which includes
MyoD, myogenin, Myf-5, and MRF4 (11, 31, 45) . Activation of muscle-specific genes by the MRFs occurs through their heterodimerization with the E protein b-HLH factors (28) and subsequent binding to E-box DNA consensus sequences (CA NNTG) (9) . MRFs thus transactivate muscle-specific genes and efficiently convert nonmuscle cells to the myogenic lineage (45) . p300/CBP and P/CAF coactivators have acetyltransferase activities and regulate transcription, cell cycle progression, and differentiation. They are both required for MyoD activity and muscle differentiation (34, 39) . In contrast, histone deacetylation inhibits gene activation, and the interaction between histone deacetylase 1 (HDAC1) and MyoD prevents premature activation of the myogenic program in growing myoblasts (25) .
MyoD is expressed in proliferating myoblasts and causes efficient withdrawal from the cell cycle prior to the differentiation process. The cyclin-dependent kinase (Cdk) inhibitors p21 and p57 Kip2 , which negatively regulate cell cycle progression (19) , play an important role in this process. Both of these proteins are highly expressed during muscle differentiation, both in embryos and in tissue culture (37, 50) . MyoD is responsible for up-regulating p21 in muscle cells that have been induced to differentiate in vitro (17, 32) . The MyoD level appears to be tightly controlled in growing myoblasts (22) . Phosphorylation of MyoD at serine 200 plays a crucial role in modulating its half-life and its transcriptional activity during myoblast proliferation (21, 41) . MyoD is degraded by the ubiquitin-proteasome pathway (3, 44) . Up-regulation of p57 Kip2 stabilizes MyoD by blocking cyclin E-Cdk2 activity (36) and by direct interaction with MyoD (37) .
Ectopic expression of p21 induces G 1 (18) and G 2 arrest in mammalian cells (29) . p21 may also play a role during the G 2 /M-phase transition by inducing pause, thereby facilitating the integration of critical G 2 checkpoint signals that regulate entry into mitosis (10) . Overexpression of p21 induces growth arrest and a senescent phenotype by selectively inhibiting a set of genes involved in mitosis, DNA replication, segregation, and repair (5) . Based on the evidence that tumor cells lacking these proteins enter into mitosis with accelerated kinetics (4, 6) , p53, p21, and 14-3-3 are necessary to maintain a G 2 arrest following DNA damage. Nonetheless, the G 2 checkpoint is maintained by redundant pathways (33) . The transactivation of p21 may dictate the duration of G 2 phase through an initial inhibition of cyclin B-Cdc2 activity (12, 40) .
Cells isolated from adult MyoD-null mice are unable to progress through the normal differentiation program and are mitotically active under conditions that initiate terminal differentiation in wild-type cells (27) . MyoD directly orchestrates multiple subprograms of gene expression. Temporal patterning of gene expression is achieved through promoter-specific regulation of MyoD binding (1) . Recent data indicate that MyoD has distinct transcriptional activities in growing and differentiating myoblasts. Moreover, MyoD has a bimodal pattern of expression in the course of cell cycle division (20, 44) . Thus, MyoD may control specific myogenic programs in cycling myoblasts.
In the present work we addressed the possibility that periodic expression of MyoD in the cell cycle might constitute a mechanism for regulating its myogenic functions in proliferating cells. We show that MyoD protein levels increase in G 2 and that MyoD is phosphorylated on Ser5 and Ser200 by cyclinBCdc2, resulting in its destabilization before entry into mitosis.
Replacement of these two serines by nonphosphorylable alanine prevents MyoD phosphorylation and delays entry into mitosis. We find that the mutant MyoD A5/A200 displays increased interaction with the coactivator P/CAF, whose binding stimulates the MyoD-mediated transcriptional transactivation of chromatin-integrated p21 promoter-luciferase (p21-Luc). We show that cyclin B-Cdc2-mediated phosphorylation of MyoD destabilizes the MyoD interaction with P/CAF and thus represses the transactivation of p21. These results reveal that proliferation and expression of transcriptionally active MyoD are compatible and that phosphorylation of MyoD can result in its effective functional inactivation.
MATERIALS AND METHODS
Expression vectors and purification of proteins. Expression vector pCMV-HA-MyoD was generated by cloning three hemagglutinin epitope tags at the amino termini of cDNA MyoD inserts in pcDNA3 (Invitrogen). MyoD mutant derivatives were obtained by oligonucleotide-directed mutagenesis by using a Quick Change site-directed mutagenesis kit (Stratagene) as instructed by the manufacturer. p21-Luc was constructed by inserting the HindIII-EcoRV fragment of pJFCAT (obtained from B. Vogelstein), filled in by the Klenow polymerase fragment and cloned into the SmaI site of the pGL3 basic expression plasmid (Promega). For the Gal4 fusion experiments, we cloned sequences from MyoD and MyoD,A5/A200 into the pM vector (Clontech). The reporter plasmid 5XGal4-E1b-luc was constructed by replacing the CAT reporter gene with the Luc reporter gene in the pG5E1bCAT construct. All constructions were verified by sequencing with an ABI automatic laser fluorescence sequencer.
Cell culture and DNA transfection. The mouse skeletal muscle cell line C2C12 and the fibroblastic cell line 10T1/2 were maintained in Dulbecco's modified Eagle's medium supplemented, respectively, with 20 or 15% fetal calf serum. T-Rex-293 cells (Invitrogen) were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 5 g of blasticidin/ml. The HCT116 human colon carcinoma cell line and a derivate cell line, HCT116 p21 Ϫ/Ϫ , in which both p21 Waf1/Cip1/Sdi1 alleles have been deleted through homologous recombination (4), were kindly provided by Guido Kroemer (Gustave Roussy Institut, Villejuif, France) and maintained in culture in McCoy's (Invitrogen) supplemented with 10% fetal bovine serum.
Myogenic C2C12 cells were transfected by the calcium phosphate procedure, and synchronization was done as previously described (20) . 10T1/2 fibroblasts, T-Rex-293, and both HCT116 cell lines were transfected by using JetPEI (Qbiogene). Cells were plated in 6-well plates and transfected 24 h later with a total of 3 g of various combinations of plasmids as indicated in the legends to the figures. The total amount of DNA used for each plate was normalized with the respective empty expression vehicle. One hundred nanograms of the pEGFP-C1 plasmid (Invitrogen) was included in transfection as an internal control for transfection efficiency and flow cytometry. The stable cell line of 10T1/2 cells expressing the luciferase gene under the control of the p21 promoter (p21-Luc) was obtained by cotransfection of the p21-Luc vector and the pSV2neo vector. T-Rex-293 cells were transiently transfected with pcDNA4-IRES-GFP expression vehicle encoding MyoD and MyoD,A5/A200, and expression of the corresponding vectors was induced by addition of tetracycline to a final volume of 10 g/ ml. Cells were synchronized for cell division as follows. Twenty-four hours after transfection, T-Rex-293 cells were first treated 17 h with 2 mM thymidine, released for 12 h, and arrested at the G 1 /S transition with a second treatment with 2 mM thymidine for 17 h. After washing out the thymidine, the cells were cultured 6 h to allow S-phase progression with the addition of tetracycline to a final volume of 10 g/ml to induce plasmid expression. Finally, the cells were treated for 12 h with 0.1 g of nocodazole/ml to arrest at the G 2 /M transition.
Forty-eight hours after transfection, determination of luciferase activity was done in triplicate and repeated at least twice with cell extracts normalized to protein content and normalized for transfection efficiency with a cotransfected pCMV-green fluorescent protein (GFP) reporter and by Western blotting of the MyoD proteins in the cell extract, with similar results.
Cell staining, flow cytometry, and cell sorter experiment. At the indicated time points, the cells were harvested via trypsinization, washed in PBS 1X, and fixed in 85% (vol/vol) methanol for 30 min at Ϫ20°C. Cells were pelleted and resuspended in 100 l of staining buffer (10 g of bovine serum albumin/ml, 0.05% saponin, 1ϫ PBS) containing a 1:100 MPM-2 dilution of MPM-2 antibody for 1 h. The cells were then washed and incubated 45 min at room temperature in staining buffer containing a 1:200 dilution of phycoerythrin-conjugated secondary rabbit antibody (Jackson) and 10 g of Hoechst/ml. Cells were analyzed in a Becton Dickinson FACS VANTAGE SE. Cell cycle data were plotted with Cell Quest software (Becton Dickinson) in a FACS VANTAGE SE (argon laser 333 to 363 nm [COHERENT]), and axis scales were optimized by using the control sample and maintaining that value for each sample. For the cell sorter experiment, approximately 2.10 6 cells per ml were incubated for 30 min at 37°C with 10 g of Hoechst (Sigma)/ml in medium with 15% fetal calf serum. Cells from different fractions were collected by centrifugation, washed in PBS 1X, and lysed in immunoprecipitation (IP) buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 10% glycerol, 0.5% NP40, 0.5 mM Na-orthovanadate, 50 mM NaF, 80 mM ␤-glycerophosphate, 10 mM Na-pyrophosphate, 1 mM dithiothreitol, 1 mM EGTA, 10 g of leupeptin/ml, 10 g of pepstatin/ml, and 10 g of aprotinin/ml). Immunological reagents and procedures. Immunoprecipitation and Western blotting were performed as previously described (36, 37) unless otherwise specified. Gel loading was normalized to protein concentration. Signals were quantified by Gelscan. Antibodies used included the following: anti MyoD monoclonal antibody diluted to 1/300 with 5A8 (Pharmingen), anti-MyoD polyclonal antibody diluted to 1/500 with C-20, anti-Cdc2 diluted to 1/1000 with M-2, anti cyclin-B diluted to 1/1,000 with M-20, anti-p21 diluted to 1/250 with F5, and anti-p300 polyclonal antibody diluted to 1/500 with C-20 (all from Santa Cruz). Anti-hemagglutinin (HA) antibody was diluted to 1/1,000 with 12CA5 (Roche). The monoclonal antibody ␣-tubulin was diluted to 1/5,000 with DM1A, and anti-Flag was diluted to 1/1,000 with M2 (Sigma).
Metabolic labeling. Thirty-six hours after transfection, cells were labeled with [ 32 P]orthophosphate (0.5 mCi ml Ϫ1 ) in phosphate-free medium for 2 h. Cells were lysed in IP buffer precleared for 30 min with protein-G beads and immunoprecipitated for 3 h with anti-MyoD polyclonal antibody (C-20). Immunoprecipitates were washed four times in IP buffer and then resuspended in sodium dodecyl sulfate (SDS)-sample buffer and resolved on a 10% polyacrylamide gel. Immunoprecipitated proteins were transferred to nitrocellulose and visualized by autoradiography.
Cycloheximide treatment was carried out essentially as described previously (37) .
Cyclin B-Cdc2 kinase assays and phosphatase treatment. Production and purification of full-length murine MyoDwt, MyoDA5, MyoDA200, and MyoD,A5/A200 bacterially produced proteins were purified essentially as described (44) . Active cyclin B-Cdc2 was obtained by immunoprecipitation with anti-Cdc2 antibody. Cyclin B-Cdc2 complexes were incubated at 30°C for 30 min with purified recombinant proteins (2 g) in a 30-l reaction mixture containing 50 mM HEPES (pH 8.0), 10 mM MgCl 2 , 2.5 mM EGTA, 1 mM dithiothreitol, 10 M ␤-glycerophosphate, 1 mM NaF, 0.1 mM Na 3 VO 4 , 0.1 mM phenylmethylsulfonal fluoride, 10 M ATP, and 150 kBq of [␥ 32 P]ATP (5,000 Ci/mmole; ICN). The reaction products were separated on SDS-polyacrylamide gel electrophoresis (PAGE), and phosphorylated proteins were transferred to nitrocellulose and visualized by autoradiography. Phosphatase treatments were done essentially as described previously (36) .
RESULTS
Accumulation of MyoD in G 2 phase is followed by phosphorylation in mitosis. In C2 myoblasts released from the quiescent G 0 stage, MyoD manifests a bimodal expression pattern in the course of the cell division cycle with high levels in mid-G 1 and in late G 2 (20) . The destruction of the MyoD protein at late G 1 , just before the incipient S phase, is mediated by the ubiquitin-proteasome system, a process that is triggered by direct cyclin E-Cdk2-dependent phosphorylation of MyoD on serine 200 (44) . As shown in Fig. 1A , the amount of MyoD protein remained low throughout the S phase, rose during G 2 , and dropped again in mitosis while exhibiting a shift to a slowly migrating form (Fig. 1A) . The mitotic arrest of C2C12 myoblasts by nocodazole resulted in a strong phosphorylation of MyoD, which migrated with a slower mobility in the mitotic fraction (shake-off fraction that consisted of ϳ85% of cells containing condensed chromatin as judged by propidium iodine labeling of fixed cells) compared to that for the nonmitotic fraction (Fig. 1B) . When exposed to lambda phosphatase, 1810 TINTIGNAC ET AL. MOL. CELL. BIOL.
MyoD from mitotic cells reacquired a normal gel mobility (Fig.  1C) , indicating that its reduced mobility was indeed due to phosphorylation (Fig. 1C) . In addition, the total amonts of MyoD appear to be significantly diminished in mitotic cells. Cyclin B-Cdc2 mediates phosphorylation of MyoD Ser5 and Ser200. MyoD has previously been shown to be phosphorylated in vitro by cyclin B-Cdc2 on serine 5 (located in the transactivation domain) and serine 200. Only serine 200 was found to be phosphorylated in vivo, in asynchronous myoblasts which contain only a few mitotic cells (21) . Because Cdc2 is known to be active at the G 2 /M transition and during mitosis, we investigated whether cyclin B-Cdc2 kinase would cause the phosphorylation of MyoD Ser5 and Ser200. We first mutated Ser5 to Ala5 (MyoD,A5) or Ser200 to Ala200 (MyoD,A200) and/or both Ser5 and Ser200 to Ala5 and Ala200 (MyoD,A5/ A200) and then analyzed recombinant MyoD protein in an in vitro kinase assay using immunoprecipitated cyclin B-Cdc2 complexes from nocodazole-treated cells. As shown in Fig. 2A , cyclin B-Cdc2 isolated from nocodazole-treated myoblasts efficiently phosphorylated MyoDwt, MyoD,A5, and MyoD, A200, whereas phosphorylation of mutant MyoD,A5/A200 was strongly reduced. We then investigated whether Ser5 and Ser200 in MyoD could be phosphorylated in vivo. Expression vectors encoding MyoDwt or mutant derivatives were transfected in 10T1/2 cells, and MyoD phosphorylation was monitored in total extracts of nocodazole-treated cells labeled with [ 32 P]orthophosphate. Immunoprecipitation of MyoD proteins revealed that MyoDwt, MyoDA5, and MyoDA200 but not MyoDA5/A200 were efficiently phosphorylated in vivo (Fig.  2B ). Furthermore, in asynchronous cells in which only serine 200 was found phosphorylated in vivo, overexpression of transfected cyclin B-Cdc2 expression vectors increased both the number of cells in G 2 /M and the serine phosphorylation of MyoDwt, while no specific phosphorylation was observed with the MyoD mutant A5/A200 (Fig. 2C) . Altogether, these data indicate that cyclin B-Cdc2 kinase phosphorylates MyoD on Ser5 and Ser200. This prompted us to investigate the effect of mutations on both Ser5 and Ser200 on MyoD during G 2 /M transition.
Cyclin B-Cdc2 phosphorylation represses MyoD-dependent transactivation. Reversible phosphorylation of the transcriptional machinery represses transcription at mitosis either by inhibiting DNA-binding activity or by suppressing transcription initiation (15, 26, 30, 38) . We examined the effect of cyclin B-Cdc2 kinase on the transactivation function of MyoDwt by measuring the ability of Gal4 DBD -MyoDwt, Gal4 DBDMyoDA5, Gal4 DBD -MyoDA200 and Gal4 DBD -MyoDA5/A200 fusion proteins to activate a Gal4-Luc reporter (pG5E1b-luc). The Gal4 DBD -MyoDwt-mediated transactivation of the reporter gene was reduced in a dose-dependent manner by coexpression of cyclin B-Cdc2 (Fig. 3A) . The impact of the MyoD phosphorylation by cyclin B-Cdc2 was further investigated by cotransfecting Gal4 DBD -MyoDwt, Gal4 DBDMyoDA5, Gal4 DBD -MyoDA200, and Gal4 DBD -MyoDA5/ A200 with the Gal4-Luc reporter with or without coexpression vectors coding for cyclin B and Cdc2. Importantly, the mutation of the Cdc2 phosphorylation sites on MyoD prevented the repression of the Gal4-Luc reporter gene by cyclin B-Cdc2 (Fig. 3B) . In this assay, the double mutation (Gal4 DBDMyoDA5/A200) had a stronger effect on both single mutations (Gal4 DBD -MyoDA5 and Gal4 DBD -MyoDA200), emphasizing the importance of both Cdc2 phosphorylation sites in the transcriptional activity of MyoD. Altogether, these results show that cyclin B-Cdc2 phosphorylation significantly represses the transactivation function of MyoD by phosphorylation of Ser5 and Ser200.
Phosphorylation of MyoD inhibits the interaction with P/CAF by recruiting HDAC1. To elucidate the mechanism responsible of the transcriptional repression of MyoD induced by cyclin B-Cdc2, we hypothesized that phosphorylation might regulate the interaction of MyoD with a critical effector molecule involved in its transcriptional activation or silencing. Because P/CAF and p300/CBP coactivators can bind to and mediate MyoD-dependent transcription, likely by histone acetyltransferase activity (35), we determined whether these coactivators would bind to MyoD. 10T1/2 cells were transfected with expression vectors encoding MyoDwt and/or the nonphosphorylable mutant MyoDA5/A200 in the absence and in the presence of p300 or P/CAF, and whole-cell extracts were 3) , Gal4 DBD -MyoDwt (lanes 4 to 6) either in the absence (lanes 1 and 4) or in the presence (lanes 2, 3, 5, and 6) of increasing amounts of cyclin B and Cdc2 expression vectors. The minus sign indicates that an empty expression vehicle has been added instead of the corresponding expression plasmids. CycB, cyclin B. (B) 10T1/2 cells were transfected with the Gal4x5 reporter construct together with expression vectors for Gal4 DBD , Gal4 DBD -MyoDwt, Gal4 DBDMyoDA5, Gal4 DBD -MyoDA200, or Gal4 DBD -MyoDA5/A200 in the absence (Ϫ) or the presence of cyclin B-Cdc2 as indicated. After transfection, cells were synchronized by serum and methionine deprivation. Thirty-six hours later, cells were re-fed, cells in G 2 /M were purified by cell sorter apparatus, and luciferase activity was monitored from whole-cell extracts. Values shown are means Ϯ standard deviations of three separate readings and represent the ratio of luciferase activity in the absence (Ϫ) (set at 100%) and in the presence (ϩ) of cyclin B-Cdc2. cyc B, cyclin B.
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prepared from G 2 /M enriched cells obtained by cell sorting. After being normalized for protein content, the extracts were immunoprecipitated with anti-MyoD antibodies. The immunoprecipitates were then examined for the presence of p300 or P/CAF by immunoblotting. As shown in Fig. 4A , there was no association between MyoD or MyoDA5/A200 and p300. In the same conditions, an interaction between P/CAF and MyoDA5/ A200 was clearly observable, suggesting that cyclin B-Cdc2 phosphorylation might control the ability of P/CAF to associate with MyoD. MyoD is acetylated in vivo and forms a complex with P/CAF that is readily detectable in proliferating muscle cells (39) . To corroborate that the association between MyoD and P/CAF can occur at endogenous levels, synchronized C2C12 myoblasts were harvested at the G 2 /M block. Total cellular extracts were first immunoprecipitated with antiMyoD antibodies, and then the immunoprecipitates were examined for the presence of P/CAF by Western blotting. As shown in Fig. 4B , there was hardly any association between MyoD and P/CAF in mitosis. In contrast, in G 2 and in asynchronous myoblasts, an interaction between these two proteins was clearly observable. Recently, HDAC1 has been shown to inhibit the ability of P/CAF to augment the MyoD-dependent transcription in vivo, suggesting that HDAC1 normally plays a role in silencing the transcriptional activity of MyoD. As MyoD can associate with HDAC1 in undifferentiated cells and this interaction is direct (25), we investigated whether HDAC1 would interact with MyoD,A5/A200 and MyoDwt to the same extent. Mutation of Ser5 and Ser200 to nonphosphorylable alanine residues led to a ϳ50 to 60% reduction in the HDAC1-MyoD coimmunoprecipitation (Fig. 4B) , indicating that phosphorylation of MyoD favors its association with HDAC1 in vivo.
MyoD mediates p21 accumulation at the onset of mitosis. Several redundant pathways maintain a G 2 checkpoint in which p21 may initially inhibit cyclin B-Cdc2, thus inducing a pause that regulates entry into mitosis (33) . Because p21 is a downstream target of MyoD in myogenic cells (17), we evaluated whether MyoD could affect p21 expression in G 2 /M transition by examining the activity of a chromatin-integrated p21-responsive reporter (p21-Luc) and by determining the induction of endogenous p21 protein. We stably transfected the luciferase gene under the control of the promoter of p21 (p21-Luc), and we first monitored the activation of the luciferase reporter placed under the control of the p21 promoter by MyoDwt and MyoD,A5/A200. Whole-cell extracts from G 2 /Menriched cells were prepared for luciferase activity and Western blot expression of MyoD proteins. As shown in Fig. 5A , we observed a much higher activation of p21-Luc by MyoD,A5/ A200 than by MyoDwt. Under the same conditions, a GFP protein placed under the control of the MCK promoter was repressed in cycling cells and induced only in differentiating cells (data not shown).
To address the biological role of the MyoD-dependent accumulation of p21, we determined whether p21 accumulating during G 2 would inhibit the activity of the cyclin B-Cdc2 complex. Cell lysates from synchronously proliferating C2C12 myoblasts were first analyzed by Western blot for MyoD, cyclin B, Cdc2, and p21 levels during G 2 to G 1 transition. In Fig. 5B , we show that p21 levels rapidly decreased as C2C12 myoblasts entered into mitosis and became detectable again only as cells approached the next G 1 phase. To determine whether p21 is associated with active or inactive cyclin B-Cdc2 complexes (47) , cell lysates were immunoprecipitated with anti-p21 antibodies and the immunoprecipitates were sequentially analyzed by Western blot for cyclin B, Cdc2, and p21. As shown in Fig.  5C , both cyclin B and Cdc2 coimmunoprecipitated with p21 in G 2 . Furthermore, samples of the same lysates were immunoprecipitated with anti-cyclin B antibodies, and immunoprecipitates were analyzed for cyclin B-associated kinase using histone H1 as the substrate. During G 2 phase progression, a low level of cyclin B-associated kinase activity was observed in the presence of high levels of p21, and entry into mitosis was confirmed by a sharp rise of cyclin B-associated kinase activity ( Fig. 5C and E) . As expected, the cyclin B-associated kinase activity is high during mitotic progression and declined abruptly when myoblasts reentered G 1 (7) . Altogether, these results strongly suggest that a MyoD-mediated modulation of p21 protein levels participates in the control of the cyclin B-Cdc2 kinase activity during the G 2 phase.
Inducible expression of mutant MyoD,A5/A200 delays mitotic entry. We examined whether loss of phosphorylation of MyoD would delay the entry into mitosis. We first used the tetracyclin-inducible expression system and created pcDNA 4 -IRES-GFP derivatives containing MyoDwt or MyoDA5/A200 and transfected T-Rex-293 cells that stably express the Tet repressor. Addition of tetracycline to the culture medium induced high levels of MyoD proteins that up-regulated p21 protein expression (Fig. 6A) . Because high levels of MyoD protein induce significant G 1 arrest, expression vectors encoding the MyoD proteins were activated by tetracycline after the release from G 1 /S block, in the presence of nocodazole, followed by recovery of the nonmitotic and mitotic fractions according to the experimental scheme illustrated in Fig. 6B . GFP-positive cells in G 2 /M were purified by fluorescence-activated cell sorter (FACS), and aliquots were first analyzed for the cyclin B-associated histone H1 kinase activity. Comparative analyses revealed that the cyclin B-Ccd2 activity of cells transfected by the nonphosphorylable MyoD-A5/A200 mutant was strongly reduced (by 75%) compared to that for cells transfected with MyoDwt (Fig. 6C) . Secondly, cells were coated on poly-L-lysine plates with fresh medium, and 0 or 90 min after release from the G 2 /M block, we analyzed MyoDwt, MyoD,A5/ A200, and p21 protein expression by immunoblotting. Degradation of cyclin B, which occurs in metaphase-anaphase transition (7), was used to control exit from mitosis. Indeed, 90 min after nocodazole release, cells transfected by the vector alone or encoding MyoDwt exited from mitosis and showed a downregulation of p21 and MyoDwt, respectively (Fig. 6D ). In contrast, cyclin B degradation was not observed in MyoD,A5/ A200-expressing cells which maintained, to a lesser extent, MyoD and p21 protein expression. These findings suggest that MyoD,A5/A200 may be efficient in blocking entry into mitosis and/or in delaying exit from mitosis, probably by sustaining p21 expression. To answer this question, nocodazole-blocked cells were coated on poly-L-lysine plates, and 0 or 3 h after release from nocodazole block, the frequency of mitotic cells was determined by immunostaining with the MPM-2 antibody (which stains mitotic phosphoproteins) (8) and by cytological examination. In the control cells transfected with vector only, more than 20% of GFP ϩ cells were MPM-2 ϩ . Three hours after (A) 10T1/2 fibroblasts were cotransfected with plasmids encoding P/CAF or p300 together with MyoDwt or MyoD,A5/A200 as indicated. After transfection, cells were rendered quiescent by serum and methionine deprivation for 36 h. After stimulation with serum and fresh medium, cells in G 2 /M were purified by FACS, as described in Materials and Methods, and total cell extracts were first immunoprecipitated by anti-MyoD polyclonal antibodies. Western blot analyses for the indicated proteins are shown for either the input cell lysates or for material immunoprecipitated with anti-MyoD. Immunoprecipitates were then analyzed by Western blot with specific monoclonal antibodies for HA-MyoD, p300, or pFlag-P/CAF. (B) C2C12 myoblasts were cultured in high-mitogen medium (20% fetal calf serum containing proliferative medium [Ass]) for 48 h. C2C12 myoblasts were arrested in quiescence (G 0 ) by incubation in methionine-depleted medium containing 1% serum for 30 h. Cells were released by addition of serum for 20 h in the presence of 500 nM nocodazole before shake-off treatment. The shake-off fraction (M, mitotic) and the adherent fraction (G 2 ) were harvested and extracts (200 g) from each time were analyzed by Western blot for cyclin B, MyoD, and P/CAF expression, respectively (input). release from nocodazole block, the majority of GFP ϩ cells were in G 1 , and only a low percentage were in mitosis (3 to 4% GFP/MPM2 ϩ ). Transfection of 293 cells with expression vector encoding MyoDwt yielded comparable results. At time zero, 20% of GFP ϩ cells were MPM-2 ϩ , and 3 h after release from nocodazole block the great majority of cells (Ͼ90%) had entered the G 1 phase. In contrast, cells expressing the MyoD A5/A200 mutant showed a delayed passage through the mitosis. At time zero, only 4% of the GFP-positive cells were MPM-2 ϩ , and 3 h later more than 15% of GFP positive cells were in mitosis, as judged by positive staining for MPM-2 and the cytological examination (condensed chromosomes and nuclear envelope breakdown) (Fig. 6E) . These observations suggest that conditional expression of a nonphosphorylable MyoD,A5A/A200 in T-Rex-293 cells delays entry into mitosis.
To confirm that MyoD participates via p21 in the G 2 checkpoint, we took advantage of the HTC 116 cell line and its p21 Ϫ/Ϫ derivative (4). Both cell lines exhibited mitotic arrest in response to nocodazole treatment (Fig. 7A) . pcDNA 4 -IRES-GFP derivatives containing MyoDwt or MyoDA5/A200 were transfected in HTC116 wild-type and/or HTC116p21 Ϫ/Ϫ cells, and MyoD and p21 protein expression was determined in total extracts from nocodazole-treated cells. As shown in Fig. 7B , enforced expression of MyoDwt and/or MyoD A5/A200 induced a slight increase in p21 expression in the parental HTC116 wild-type cells, while no p21 synthesis occurred in HTC116 p21
Ϫ/Ϫ cells. Transfected cells were released from nocodazole block, and the frequency of mitotic GFP ϩ cells was determined by MPM-2 staining at time zero and 3 h after nocadazole removal. As described above for T293 cells, expression of vector alone or a vector encoding MyoDwt led to comparable results. Three hours after release from nocodazole block, more than 75% of GFP-positive cells had gone through mitosis and were in G 1 . Expression of MyoD A5/A200 led to a delay in mitosis in p21-sufficient HTC116 cells. Thus, 3 h after release from nocodazole block, more than 50% of GFP-positive cells were in mitosis (MPM-2 ϩ ) (Fig. 7C) . In strict contrast, p21-deficient HTC116 p21 Ϫ/Ϫ cells expressing either MyoDwt or MyoDA5/A200 entered mitosis with indistinguish- able, normal kinetics (Fig. 7C) . These results indicate that a nonphosphorylable MyoD delays M-phase entry by sustaining p21 expression. Phosphorylation of MyoD in late G 2 is required for its rapid degradation. Phosphorylation may be involved in the degradation of MyoD as well as in its transcriptional activity (21, 41, 44) . The abundance of MyoDwt and MyoD,A5/A200 was measured in adherent (G 2 ) and mitotic shake-off (mitosis) 293 cells, obtained as schematized in Fig. 6B , after tetracyclinmediated induction of the protein. Cells from the adherent fractions were recultured in the presence of fresh medium without nocodazole, and total cell lysates were analyzed by Western blot at various times after release of nocodazole block. As shown in Fig. 8A , MyoDwt cells entered into mitosis, as determined by the total disappearance of inactive phosphorylated Cdc2 (Cdc2-PTyr15) and the decrease in MyoD levels. In contrast, MyoD,A5/A200 cells were blocked in G 2 , as evidenced by high levels of inactive Cdc2-PTyr15. Three hours after replating, a large amount of MyoD,A5/A200 cells entered into mitosis, correlating with the disappearance of Cdc2-PTyr15. During the same period, MyoDwt protein levels were remarkably stable. On the other hand, by releasing the shakeoff fractions in fresh medium leading to mitotic exit, we confirmed that MyoDwt cells passed through mitosis. Three hours later, MyoDwt cells were effectively in G 1 and showed increasing amounts of MyoD proteins and inactive Cdc2 (Cdc2-PTyr15). In contrast, MyoD,A5/A200 cells exhibited a delayed entry into mitosis, while the abundance of MyoD,A5/A200 protein decreased slowly. It is well known that the sharp increase of cyclin B-Cdc2 activity just before entry in mitosis is essential for proper execution of mitotic events (10) . To dissect the mechanisms that determine the abundance of MyoD, we examined the stability of MyoD wild type and MyoD,A5/A200 in adherent and mitotic shake-off fractions. Inhibition of protein synthesis by cycloheximide allowed us to estimate that MyoDwt had a half-life of ϳ40 min and that MyoD,A5/A200 had a half-life of ϳ120 min (Fig. 8B ) in adherent cells. In contrast, in the mitotic shake-off fractions, both MyoDwt and MyoD,A5/A200 were extremely stable, as judged by extended half-lives of up to 3 h. Addition of the proteasome inhibitor MG132 to the culture medium of adherent fractions confirmed that MyoDwt is destabilized in late G 2 via the proteasome pathway (Fig. 8C) . Altogether, these results suggest that phosphorylation and a phosphorylation-independent pathway, which is probably specific to the G 2 phase, could be implicated in MyoD degradation.
DISCUSSION
MyoD and Myf-5 exhibit a distinct profile of cell cyclespecific expression in myoblasts (20, 23, 24) . Recently, MyoD has been found to regulate genes expressed at different times during myogenesis by promoter-specific binding, thus contributing to the regulation of gene expression in normal differentiation (1, 2) as well as in undifferentiated proliferating muscle cells (46) . In synchronized myoblasts emerging from quiescence, MyoD shows a bimodal pattern of expression (20, 44) . In growing myoblasts, the phosphorylation and degradation of MyoD have been shown to represent the regulatory checkpoint that controls the decision to undergo a G 1 3G 0 transition with terminal differentiation (22) . The present data are consistent with the notion that reaccumulation of transcriptionally active hypophosphorylated MyoD participates in the control of the G 2 /M transition by modulating cyclin B-Cdc2 kinase via p21 expression, a process most likely mediated by P/CAF. This data sheds light on a new regulatory pathway in which MyoD is transcriptionally active in proliferating myoblasts.
Phosphorylation of MyoD has been recognized to suppress the MyoD-mediated myogenic differentiation (16, 36) . Phosphorylation of Ser200 by cyclin E-Cdk2 kinase is required to induce degradation of MyoD in response to growth factors, whereas neither Cdk4 nor Cdk5 is able to phosphorylate MyoD (21, 44, 48, 49) in spite of the fact that both Ser5 and Ser200 are potential (Ser/Thr-Pro) CDK consensus sites (42) . In contrast, cyclin B-Cdc2-mediated phosphorylation of both Ser5 and Ser200 has been observed in vitro (21) (Fig. 2) and in vivo after entry into mitosis when cyclin B-Cdc2 complexes become physiologically active and essential for progression through mitosis ( Fig. 1 and 2) . Phosphorylation of the transcriptional machinery is implicated in its repression at mitosis, and changes in chromatin structure and occupancy of promoter elements by both general and gene-specific transcription (17 h). During the release period in drug-free medium, tetracyclin was added, followed by nocodazole (12 h). When the cells detached from the plate with a rounded phenotype, indicating a G 2 /M enrichment, the shake-off fraction (mitotic) and adherent fraction (G 2 ) were harvested together and coated on polylysine plates and/or separately replated to be collected at the indicated point. (C) GFP-positive cells gated in G 2 /M were purified and analyzed for cyclin B-associated histone H1 kinase. Whole-cell extracts (200 g) were immunoprecipitated with antibodies to cyclin B and assayed for kinase activity by using histone H1 as substrate. Cells in G 1 were used as negative controls. (D) GFP-positive cells gated in G 2 /M as described in panel B were purified and replated in fresh medium in the absence of nocodazole and then harvested at the indicated time. Cells incubated with nocodazole but in the absence of tetracycline were used as controls (Ϫ). Total cellular extracts were separated in SDS-PAGE and after transfer on nitrocellulose membranes, proteins were analyzed for cyclin B, MyoD, Cdc2, and p21 expression by immunoblotting (left panel), and a graphic display of intensities of MyoD and p21 are shown (right panel). The signals were quantitated by a Gelscan (Pharmacia). (E) Cells coated on polylysine plates according to the scheme shown in panel B. They were released from nocodazole block by addition of fresh medium and then treated for immunofluorescence microscopy at time zero and 3 h after release. The frequency of mitotic cells was determined after immunostaining of MPM-2 antigens and cytological aspect of GFP-positive cells was also determined. White bars, empty vector; black bars, pcDNA 4 -MyoDwt-IRES-GFP; partially shaded bars, pcDNA 4 -MyoDA5/A200-IRES-GFP.
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factors also play a role in transcriptional silencing (15, 26, 38) . Phosphorylation of Ser200 has been implicated both in the reduction of activity and in the degradation of MyoD (21, 41) . The dual phosphorylation of MyoD is observed in vitro only after cyclin B-Cdc2 phosphorylation and in late G 2 and mitosis. During mitosis, MyoD has a half-life 2.5 times longer than in interphase (more than 100 min versus 45 min in interphase).
Mutations of both Ser5 and Ser200 inhibit the repression of the transcriptional activity of MyoD by cyclin B-Cdc2 (Fig. 3) . Together, these data suggest that Ser5, which is located in the transactivation domain of MyoD, could act as a super repressor of transcriptional activity of MyoD once it has been phosphorylated by cyclin B-Cdc2. Acetylation by the histone acetyltransferase P/CAF and p300 plays a key role in regulating the transcriptional activity of MyoD (34, 35, 39) . Association of MyoD with P/CAF has been observed throughout the myogenic process, and the interaction of MyoD with histone acetyltransferases takes place only when MyoD is hypophosphorylated (25) . Although p300/CBP and P/CAF are relatively abundant in transfected cells, we did not observe any association between MyoDwt and/or MyoD,A5/ A200 and p300 in G 2 /M-enriched cells. The simplest explanation for this result may be that the epitope recognized by the HA antibody became inaccessible because of the binding of p300, thus precluding a coimmunoprecipitation. However, the histone acetyltransferase activity of P/CAF but not that of p300 has recently been reported to be important for endogenous p21 expression and cell cycle arrest in myogenic cells (35) . Preferential interaction between hypophosphorylated MyoD and P/CAF could modulate the specific transcriptional activity of MyoD (Fig. 9) . Indeed, the association between endogenous P/CAF and endogenous MyoD was observed in G 2 (when MyoD is not phosphorylated). The interaction between P/CAF and nonphosphorylabel MyoD,A5/A200 was stronger than that with wild-type MyoD, again suggesting that phosphorylated MyoD may fail to interact with P/CAF, which would thus preclude its P/CAF-mediated acetylation and activation. HDAC1 can repress transcription by binding to MyoD in growing cells (25) . Indeed, we found that phosphorylation of MyoD increases its interaction with HDAC1 (Fig. 4B) , which may repress the interaction with P/CAF and hence the transcriptional actvity of MyoD. During the early phases of myogenic differentiation, the level of CKI p57 Kip2 increases markedly and induces the accumulation of hypophosphorylated MyoD (36) . Thus, phosphorylation and acetylation processes are closely implicated in the control of the transcriptional activity of MyoD.
It is presently assumed that the main targets for MyoD are the genes involved in the terminal differentiation process of muscle cells, a process that would depend on proper environmental conditions, such as reduced growth. It remains unclear why MyoD is expressed in undifferentiated myoblasts. MyoD expression is observed immediately following the activation of quiescent satellite cells, prior to the expression of proliferating cell nuclear antigen, or to the induction of cell proliferation. Mice lacking both Myf-5 and MyoD exhibit a complete absence of myoblasts, and MyoD-null mice are defective for satellite-cell activation. These observations suggest that MyoD regulates myoblast genes that are distinct from the MyoDregulated genes that are necessary for terminal differentiation. Indeed, MyoD exhibits distinct transcriptional activity in growing myoblasts as well as a unique embryonic expression pattern (1, 2, 46 ). An increase in MyoD protein levels in G 2 and a decrease in mitosis raised the possibility that MyoD might play a role in G 2 /M transition. Our data demonstrate that before the cells enter mitosis MyoD transcriptionally transactivates the p21 gene. Thus, MyoD and p21 exhibit a parallel pattern expression in synchronized myoblasts (Fig. 5 and data not shown). p21 acts primarily as a negative cell cycle regulator of the G 1 /S arrest (6) . Its reaccumulation in G 2 phase contributes to the implementation of the late cell cycle checkpoint. Several distinct mechanisms have been postulated for how p21 participates in inhibiting Cdc2 activity and causing G 2 arrest (43) . p21 may repress CDK activity by binding directly to cyclin B-Cdc2 complexes (2) (Fig. 5) . Moreover, p21 reduces the active phosphorylation of Cdc2 of threonine 161 by Cdk-activating kinase (40) . Near the end of G 2 but before the prophase, cyclin B accumulates in the cytoplasm (7) . Abrupt relocalization of cyclin B to the nucleus occurs shortly before chromatin condensation and entry in mitosis (10) . In late G 2 , cyclin BCdc2 phosphorylates MyoD, resulting in its destabilization and in the repression of its transcriptional activity. These events suppress the ability of MyoD to activate p21 promoter. In contrast, elevated levels of p21 protein in response to expression of nonphosphorylable mutant MyoD maintain low levels of Cdc2 kinase, conferring a reversible G 2 pause in myoblasts. Altogether, this scenario supports the role for cyclin B-Cdc2 phosphorylation of MyoD in the control of its transcriptional activity and stability in G 2 /M transition. VOL. 24, 2004 MUTANT MyoD DELAYS M-PHASE ENTRYMyoD protein reaccumulating in the G 2 phase must be degraded before cells enter into mitosis. MyoD degradation is triggered by its phosphorylation and presumably occurs in a proteasome-dependent fashion, as suggested by the fact that a proteasome inhibitor prevents degradation of phosphorylated MyoD in G 2 (Fig. 8) . However, in mitosis MyoD is stabilized irrespective of its phosphorylation status, suggesting that the molecular mechanism implicated in its degradation acts only in late G 2 . Identification of a functional D-box motif in the b-HLH domain of MyoD leads us to hypothesize that MyoD could be a substrate of the anaphase-promoting complex (APC)-cyclosome complex. Our results indicate that neither the CDC20 nor the CDH1 coactivators of APC interact in vitro or in vivo with MyoD (unpublished data). Recently, a D-boxlike motif overlapping the basic domain has been implicated in the constitutive instability of Myf-5 in mitosis (24) . However, the degradation of Myf-5 in mitotic cells involves a mechanism distinct from that which regulates known substrates of APC. Furthermore, a version of this motif mutated by substitution of a single residue (Q101), which more closely resembles the homologous motif present in MyoD, also has a stabilizing effect on Myf-5 in mitosis (24) . These findings suggest that the b-HLH region of MyoD and Myf-5 might determine their different stability in mitosis and may participate in recognition of phosphorylated MyoD by a different ubiquitin ligase targeting it to proteasome-mediated degradation. Alternatively, it may be speculated that the D-box of Myo D could be recognized by the APC operating at a different stage of the cell cycle than that which has traditionally been assumed (13, 14) .
In conclusion, our results establish a novel role for MyoD in the cell cycle. MyoD expressed in the G 2 phase can interact with its coactivator P/CAF to stimulate p21, thus controlling cyclin B-Cdc2 kinase activity and hence progression through the G 2 /M boundary. Phosphorylation of MyoD by cyclin BCdc2 kinase results in its inaction. The dropping of MyoD below a threshold level could well represent the critical event required for triggering myoblast mitosis (Fig. 5) .
